Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Clonal hematopoiesis (CH) results from somatic genomic alterations that drive clonal
expansion of blood cells. Somatic gene mutations associated with hematologic …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

The identification of gene fusions from RNA sequencing data is a routine task in cancer
research and precision oncology. However, despite the availability of many computational …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …